These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1589 related articles for article (PubMed ID: 27284958)

  • 1. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
    Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
    Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations.
    Ross JS; Wang K; Sheehan CE; Boguniewicz AB; Otto G; Downing SR; Sun J; He J; Curran JA; Ali S; Yelensky R; Lipson D; Palmer G; Miller VA; Stephens PJ
    Clin Cancer Res; 2013 May; 19(10):2668-76. PubMed ID: 23575477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast.
    Ping Z; Siegal GP; Harada S; Eltoum IE; Youssef M; Shen T; He J; Huang Y; Chen D; Li Y; Bland KI; Chang HR; Shen D
    Oncotarget; 2016 Dec; 7(49):80655-80663. PubMed ID: 27811364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discordant HER2 status between primary breast carcinoma and recurrent/metastatic tumors using fluorescence in situ hybridization on cytological samples.
    Arihiro K; Oda M; Ogawa K; Tominaga K; Kaneko Y; Shimizu T; Matsumoto S; Oda M; Kurita Y; Taira Y
    Jpn J Clin Oncol; 2013 Jan; 43(1):55-62. PubMed ID: 23225912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer.
    Richard F; Majjaj S; Venet D; Rothé F; Pingitore J; Boeckx B; Marchio C; Clatot F; Bertucci F; Mariani O; Galant C; Eynden GVD; Salgado R; Biganzoli E; Lambrechts D; Vincent-Salomon A; Pruneri G; Larsimont D; Sotiriou C; Desmedt C
    Clin Cancer Res; 2020 Dec; 26(23):6254-6265. PubMed ID: 32943456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
    Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
    Fumagalli C; Ranghiero A; Gandini S; Corso F; Taormina S; De Camilli E; Rappa A; Vacirca D; Viale G; Guerini-Rocco E; Barberis M
    Breast Cancer Res; 2020 Oct; 22(1):107. PubMed ID: 33059724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
    Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
    Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer.
    Sokol ES; Feng YX; Jin DX; Basudan A; Lee AV; Atkinson JM; Chen J; Stephens PJ; Frampton GM; Gupta PB; Ross JS; Chung JH; Oesterreich S; Ali SM; Hartmaier RJ
    Ann Oncol; 2019 Jan; 30(1):115-123. PubMed ID: 30423024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance.
    Pfarr N; Penzel R; Endris V; Lier C; Flechtenmacher C; Volckmar AL; Kirchner M; Budczies J; Leichsenring J; Herpel E; Noske A; Weichert W; Schneeweiss A; Schirmacher P; Sinn HP; Stenzinger A
    Genes Chromosomes Cancer; 2017 Apr; 56(4):255-265. PubMed ID: 27792260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
    Chmielecki J; Ross JS; Wang K; Frampton GM; Palmer GA; Ali SM; Palma N; Morosini D; Miller VA; Yelensky R; Lipson D; Stephens PJ
    Oncologist; 2015 Jan; 20(1):7-12. PubMed ID: 25480824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
    Kurozumi S; Alsaleem M; Monteiro CJ; Bhardwaj K; Joosten SEP; Fujii T; Shirabe K; Green AR; Ellis IO; Rakha EA; Mongan NP; Heery DM; Zwart W; Oesterreich S; Johnston SJ
    Breast Cancer Res; 2020 Aug; 22(1):85. PubMed ID: 32782013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
    Gong Y; Booser DJ; Sneige N
    Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
    Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
    Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERBB2-amplified lobular breast carcinoma exhibits concomitant CDK12 co-amplification associated with poor prognostic features.
    Forster-Sack M; Zoche M; Pestalozzi B; Witzel I; Schwarz EI; Herzig JJ; Fansa H; Tausch C; Ross J; Moch H; Varga Z
    J Pathol Clin Res; 2024 Mar; 10(2):e12362. PubMed ID: 38335502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
    J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.
    Ross JS; Wang K; Khaira D; Ali SM; Fisher HA; Mian B; Nazeer T; Elvin JA; Palma N; Yelensky R; Lipson D; Miller VA; Stephens PJ; Subbiah V; Pal SK
    Cancer; 2016 Mar; 122(5):702-11. PubMed ID: 26651075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.
    Park YH; Shin HT; Jung HH; Choi YL; Ahn T; Park K; Lee A; Do IG; Kim JY; Ahn JS; Park WY; Im YH
    Oncotarget; 2015 Oct; 6(31):32027-38. PubMed ID: 26397225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
    Ross JS; Fakih M; Ali SM; Elvin JA; Schrock AB; Suh J; Vergilio JA; Ramkissoon S; Severson E; Daniel S; Fabrizio D; Frampton G; Sun J; Miller VA; Stephens PJ; Gay LM
    Cancer; 2018 Apr; 124(7):1358-1373. PubMed ID: 29338072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 80.